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and glucose are important regulators of Mg metabolism. 
Intracellular Mg plays a key role in regulating insulin 
action, insulin-mediated-glucose-uptake and vascular 
tone. Reduced intracellular Mg concentrations result 
in a defective tyrosine-kinase activity, postreceptorial 
impairment in insulin action and worsening of insulin 
resistance in diabetic patients. A low Mg intake and an 
increased Mg urinary loss appear the most important 
mechanisms that may favor Mg depletion in patients 
with type 2 diabetes. Low dietary Mg intake has been 
related to the development of type 2 diabetes and 
metabolic syndrome. Benefits of Mg supplementation 
on metabolic profiles in diabetic patients have been 
found in most, but not all clinical studies and larger 
prospective studies are needed to support the potential 
role of dietary Mg supplementation as a possible public 
health strategy in diabetes risk. The aim of this review 
is to revise current evidence on the mechanisms of Mg 
deficiency in diabetes and on the possible role of Mg 
supplementation in the prevention and management of 
the disease.
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Core tip: Diabetes is frequently associated with 
Mg deficit. The fact that most but not all diabetic 
subjects have low magnesium (Mg) and that no large 
randomised controlled trial (RCT) has been specifically 
focused on subjects with Mg deficit, diagnosed with a 
reliable technique, may help explain discrepancies of the 
role of supplemental Mg on glycemic control, and the 
impact on diabetes risk in prospective epidemiological 
studies. Different baseline Mg, metabolic control, and 
age are other potential factors that may contribute. 
Future prospective RCTs are needed to support the 
potential role of dietary Mg supplementation as a 
possible public health strategy to reduce diabetes risk in 
the population.
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Abstract
Type 2 diabetes is frequently associated with both extrace-
llular and intracellular magnesium (Mg) deficits. A chronic 
latent Mg deficit or an overt clinical hypomagnesemia 
is common in patients with type 2 diabetes, especially 
in those with poorly controlled glycemic profiles. Insulin 
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INTRODUCTION
Magnesium (Mg) is an electrolyte of chief physiological 
importance in the body, being the most abundant 
divalent intracellular cation in the cells, the second 
most abundant cellular ion next to potassium and the 
fourth cation in general in the human body[1]. 
Type 2 diabetes mellitus (DM2) is often accompanied 
by alteration of Mg status. An increased prevalence of Mg 
deficits have been identified in DM2 patients, especially 
in those with poorly controlled glycemic profiles, with 
longer duration of the disease and with the presence of 
micro- and macrovascular chronic complications[2-6].
Laboratory tests with a high sensitivity and specificity 
and easy to perform to allow an accurate clinical assess-
ment of Mg status are missing. Patients are considered 
frankly hypomagnesemic with serum Mg concentrations 
≤ 0.61 mmol/L or 1.5 mg/dL[7-9]. Mg concentrations 
≤ 0.75 mmol/L or 1.8 mg/dL may be considered as 
preclinical hypomagnesemia[10,11].
Mg deficiency can be present without hypoma-
gnesemia. However, hypomagnesemia, when present, 
is usually indicative of an important systemic Mg deficit. 
A depletion in intracellular and/or ionized plasma Mg can 
be found in individuals with normal total serum Mg[12]. 
However, most of the studies in the literature have 
measured total serum Mg instead of the free, ionized 
(bioactive) or the intracellular Mg concentrations, which 
make it a challenge to correlate Mg deficits to diseases.
We have recently confirmed that diabetic older 
patients are more prone to hypomagnesemia; this 
condition being closely related to metabolic control as 
measured by glycated hemoglobin even after adjustment 
for relevant confounders. Ionized Mg may help to identify 
diabetic older adults with low concentrations of blood Mg 
that are not evident with the only measurement of total 
Mg[12]. 
Intracellular free Mg levels are consistently reduced 
in subjects with DM2, when compared with nondiabetic 
subjects[1,13,14]. Although the mechanism has not been 
fully elucidated, an alteration in the mechanism(s) of 
the Mg uptake in the cells, and/or a deficit of ATP, may 
help to understand the cellular Mg deficit observed in 
DM2[15]. The relationship between intracellular Mg and 
ATP concentration is rather complex. The decrease 
in cellular ATP might partially explain the decrease in 
cellular Mg. Otherwise, a decrease in cellular ATP leads 
to a decreased binding of Mg to ATP in the formation 
of MgATP, which might increase the intracellular Mg 
concentration.
The aim of this review is to revise current evidence 
on the mechanisms of Mg deficiency in DM2. The evidence 
on the role of Mg supplementation in the management 
of DM2 will also discussed.
MECHANISMS OF MG DEFICIENCY IN 
DM2
Reduced Mg intake and/or augmented Mg urinary loss 
are among the most important causes of Mg deficits in 
DM2, while Mg absorption and retention seems to be 
maintained[16-18].
A relationship between Mg levels in the plasma and 
the development of DM2 in the general population has 
been suggested[19]. DM2 is frequently accompanied by 
renal calcium and Mg loss[20,21], but the mechanism(s) of 
this wasting is still not completely elucidated[22]. 
Both hyperglycemia and hyperinsulinemia may 
increase urinary Mg excretion. Urinary Mg excretion and 
fasting blood glucose have been found to be inversely 
related to serum Mg levels. Thus, hyperglycemia 
decreases Mg tubular reabsorption[20]. A good metabolic 
control is associated with a reduction of the urinary Mg 
wasting[3].
In streptozotocin-induced diabetic rats, Lee et 
al[22] found an increase in renal Mg transporters. The 
alteration was corrected by insulin administration. Insulin 
resistance and hyperinsulinemia may also affect Mg 
transport[21].
MG AND INSULIN SENSITIVITY
Hypomagnesemia in DM2 is present only in severe 
(and generally long lasting) Mg deficits. A chronic latent 
Mg deficiency without alteration in serum total Mg is 
more commonly observed[12]. These often undetected 
Mg insufficiencies have clinical importance, since Mg is 
a main co-factor in numerous enzymatic reactions (> 
300 enzymatic reactions including all the enzymes of 
glycolysis). Mg also is deeply involved in the regulation 
of insulin signaling, in the phosphorylation of insulin 
receptor kinase, in the post receptorial action of insulin, 
and in insulin-mediated cellular glucose uptake[17,23]. 
The clinical consequence of a chronic Mg deficit 
is post-receptorial insulin resistance and consequent 
reduced glucose utilization in the cells, worsening the 
reduced insulin sensitivity present in DM2[18]. 
Another possible link between Mg deficiency and 
reduced insulin sensitivity is the presence of oxidative 
stress and/or inflammation. Thus, free radicals are 
often increased in DM2, hypertension, metabolic 
syndrome and aging, conditions also associated with 
Mg deficits[24,25]. In particular, we demonstrated an 
age-dependent deficit of cellular Mg in persons aged 
65 years and over, as well as in patients with essential 
hypertension or DM2, independently of age[14,25].
Nevertheless, independently of the mechanisms 
of Mg deficits in DM2, metabolic syndrome, essential 
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hypertension and aging, it is apparent that this Mg 
deficiency may contribute to enhance the insulin resi­
stance status of these conditions[17,18]. Mg deficit could 
precede and cause post-receptorial resistance of insulin 
and alter glucose tolerance. 
MG DEFICIENCY AND CARDIO-
METABOLIC DISEASES 
Mg deficiency may be also a factor implicated in DM2 
complications. We found a relation between ionic 
changes and echocardiographic indices alterations[26]. 
We observed an significant association of reduced 
cellular Mg with cardiac hypertrophy in DM2 patients[26]. 
Cellular Mg measured in vivo in skeletal muscle and 
in the brain with 31P-NMR, was directly related to aortic 
distensibility[27]. 
Reduced Mg levels were also associated with an 
increased prevalence of arrhythmias in DM2 obese 
subjects[6], and with a more rapid decline of renal func-
tion. Thus, hypomagnesemia is currently considered 
an accurate predictor of progression of diabetic nephro-
pathy[28-30]. Mg deficits have also been associated with 
cognitive decline[31], multimorbidity[32] and agin[25,33]. 
DIETARY MG DEFICIENCY MAY 
PREDISPOSE TO DM2 
Dietary Mg deficiency may cause insulin resistance as 
shown by several studies both in humans and in exp-
erimental animals[34-40]. In sheeps, Mg-deficient diet 
caused a significant impairment of insulin-mediated 
glucose uptake[35]. In rats, Mg supplements were 
able to postpone the onset of diabetes[36]. In healthy 
women (without DM2), the higher was the intake of 
Mg, the lower were fasting levels of insulin[37]. In young, 
nondiabetic African Americans, low dietary Mg was 
associated with insulin resistance and insulin responses 
to an oral glucose tolerance test[38]. A low Mg diet in rats 
produced an increase in triglyceride and plasma glucose 
levels[39]. In rats, a maternal restriction of dietary Mg was 
able to cause insulin resistance in pups[40]. Suárez et al[41] 
suggested that the worsening of glucose metabolism 
induced by Mg dietary restriction in experimental rats 
is due to an impairment of both, insulin secretion and 
insulin action. 
Deficiencies of Mg status including both hypoma-
gnesemia and/or reduced dietary Mg intake have been 
linked to an enhanced risk to develop DM2 or glucose 
intolerance[19,42-44]. Higher Mg intakes were conversely 
associated with a reduced incidence of DM2[45].
Several studies have shown a clear association of Mg 
intake with DM2 and with cardio-metabolic syndrome, 
suggesting that a higher Mg consumption is related to 
a reduction of the incidence of these conditions. Two 
meta-analyses of prospective studies concluded that Mg 
intake is inversely associated with the onset of DM2[46,47]. 
In addition, the development of the cardio-metabolic 
syndrome has been linked to dietary Mg content[34,48]. 
Hypomagnesemia itself in a 10-year follow-up study 
was associated with glucose tolerance impairment[49]. 
Conversely, higher Mg intake was associated with 
increased insulin sensitivity[50] and with decreased risk 
of incident DM2, with a decreased risk of 0.68 in the 
higher compared with the lower quintiles[51,52]. 
Similar findings were obtained in the CARDIA study, 
during a 20-year follow-up, which also confirmed the 
reverse relationship of dietary Mg with inflammation 
markers[53]. 
POSSIBLE USE OF MG SUPPLEMENTS IN 
THE MANAGEMENT OF DM2
The detection and correction of altered Mg status in 
diabetic patients is clinically appropriate, although many 
physicians tend to ignore Mg status. The increased 
risk of developing impaired glucose tolerance and/or 
frank DM2 in persons with dietary or serum Mg deficits 
have suggested a potential benefit of Mg supplements 
in patients with DM2 or in the presence of risk factors 
for DM2. Mg supplements have been proposed as a 
complementary tool for the prevention of DM2 and its 
metabolic control[54,55]. Some benefits of Mg supplements 
on glycemic profiles have been found in most but not all 
studies. 
Regrettably, results from clinical trials are still 
limited[56]. Thus, the clinical evidence of a clear effect 
of Mg supplementation on metabolic indices in persons 
with DM2 are controversial. Some benefit has been 
found in several[8,54,57,58], but not in all clinical studies[59]. 
The hypothesis of a role of supplemental Mg in the 
control of DM2 still needs to be ascertained by large 
randomized clinical trials[60,61]. Mg supplementation 
may improve glycemic concentrations in fasting and 
postprandial states, and insulin sensitivity. We found a 
significant relationship between the increase in serum 
and cellular Mg and insulin sensitivity[62]. We also showed 
that Mg supplementation is able to improve an altered 
endothelial function in DM2 older adults[63]. Barragán-
Rodríguez et al[64] suggested a positive effect in the 
treatment of depression in older persons with DM2 
and hypomagnesemia. Presumably, the main problem 
is that all RCTs were underpowered, partially through 
overestimation of the treatment effect. Differences 
may be related to the fact that most of the existing 
studies have included a small number of subjects, using 
different Mg doses and different Mg salts. 
Several studies have linked high Mg content present 
in fiber with the positive action of whole grains to 
improve insulin sensitivity[65-68]. Oral Mg supplements 
have been shown to improve fasting and postprandial 
glucose levels and insulin sensitivity in hypomagnesemic 
DM2 patients[57], to improve insulin sensitivity in non-
diabetic subjects with insulin resistance[8], and to 
decrease C-reactive protein levels in hypomagnesemic 
patients with prediabetes[69]. 
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In summary, oral Mg supplements appear to be 
useful in persons with DM2 to restore Mg deficiencies, 
to improve insulin resistance, oxidative stress, and 
systemic inflammation. 
The absence of large trials in DM2 patients 
specifically focusing on those with Mg deficit may help 
to explain the inconsistency between epidemiological 
(mainly positive) and clinical (mostly controversial) 
studies. Since most, but not all, DM2 patients have Mg 
deficiency, it would be useful to focus on those with 
deficit in order to correct it. Differences in Mg balance, 
glycemic control, and age are other potential factors 
that may help to explain the differences among the 
studies. Most studies used total serum Mg concentration 
instead of the free, ionized (bioactive) Mg concentration, 
which make it a challenge to correlate Mg deficiency to 
diseases.
Future prospective large RCTs would be important to 
support the possible inclusion of Mg supplements in the 
guidelines for the management of DM2.
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